Asthma at the 2016 American Thoracic Society International Conference

The Year in Review in asthma was presented by Dr. Akshay Sood from the University of New Mexico, featuring several high profile articles published over the last year. Of particular interest, favorable phase 3 data were presented supporting the use of reslizumab, a humanized monoclonal antibody against IL5, in the treatment of moderate-to-severe asthma in patients with blood eosinophil counts greater than 400 cells per microliter (1). Patients receiving reslizumab had fewer asthma exacerbations over 1 year than patients receiving placebo in two duplicate studies published as a single manuscript. Reslizumab was approved earlier this year in the United States for the treatment of severe asthma.